par Attal, Michel;Lauwers-Cances, Valerie;Marit, Gerald;Caillot, Denis;Moreau, Philippe;Facon, Thierry;Stoppa, Anne Marie;Hulin, Cyrille;Benboubker, Lotfi;Garderet, Laurent;Decaux, Olivier;Leyvraz, Serge;Vekemans, Marie-Christiane;Voillat, Laurent;Michallet, Mauricette;Pegourie, Brigitte;Dumontet, Charles;Roussel, Murielle;Leleu, Xavier;Mathiot, Claire;Payen, Catherine 
;Avet-Loiseau, Herve;Harousseau, Jean-Luc;Meuleman, Nathalie ; [et al.]
Référence The New England journal of medicine, 366, 19, page (1782-1791)
Publication Publié, 2012-05
;Avet-Loiseau, Herve;Harousseau, Jean-Luc;Meuleman, Nathalie ; [et al.]Référence The New England journal of medicine, 366, 19, page (1782-1791)
Publication Publié, 2012-05
Article révisé par les pairs
| Résumé : | High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation. |
